Table 3.
Trial participation according to unit and tumor entity. Percentages are calculated according to unit and tumor entity, respectively.
| Trial “no”, n (%) | Trial “yes”, n (%) | |||
|---|---|---|---|---|
| Unit | ||||
| DERMA | 34 | (94.4%) | 2 | (5.6%) |
| GYN | 12 | (50.0%) | 12 | (50.0%) |
| HAN | 189 | (91.3%) | 18 | (8.7%) |
| HEM | 70 | (81.4%) | 18 | (18.6) |
| NEURO | 102 | (77.3%) | 30 | (22.7%) |
| ORTHO | 20 | (83.3%) | 4 | (16.7%) |
| RADONC | 102 | (80.3%) | 25 | (19.7%) |
| SUR | 94 | (75.8%) | 30 | (24.2%) |
| Tumor entity | ||||
| Bone/spine cancer/metastases | 29 | (82.9%) | 6 | (17.1%) |
| Brain tumors/metastases | 115 | (77.7) | 33 | (22.3%) |
| Breast cancer and gynecological tumors | 40 | (67.8%) | 19 | (32.2%) |
| Head and neck cancer | 194 | (90.2%) | 21 | (9.8%) |
| Hematological cancer | 58 | (77.3%) | 17 | (22.7%) |
| Hepato-pancreato-biliary cancer | 37 | (80.4%) | 9 | (19.6%) |
| Prostate cancer and urological tumors | 27 | (93.1%) | 2 | (6.9%) |
| Skin cancer | 39 | (90.7%) | 4 | (9.3%) |
| Upper and lower gastrointestinal cancer | 40 | (70.2%) | 17 | (29.8%) |
Unknown answers for the question about trial participation (n = 11) were excluded.